TITLE

THE CHANGING DYNAMICS

AUTHOR(S)
Floyd, David
PUB. DATE
March 2008
SOURCE
Management Services;Spring2008, Vol. 52 Issue 1, p14
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the growth of the global pharmaceutical industry in 2008. The world growth expected for the pharmaceutical industry is 8% per year until 2009. The industry is beginning to globalize for the improvement of skills and research capabilities. Because of an increasing ageing population, the demand healthcare products has also increased, particularly in countries such as U.S. and Japan. Factors that contribute to the industry's growth include researches, technology, communications, and international production.
ACCESSION #
31726640

 

Related Articles

  • Drug innovation drives Colorado's economy. Duke, Richard // Northern Colorado Business Report;9/20/2013, Vol. 18 Issue 27, p31 

    The author discusses the economic aspect of drug innovation in Colorado.

  • Supergenerics & The Future of Pharma. Badrot, Andrew // Contract Pharma;Mar2013, Vol. 15 Issue 2, p147 

    The article offers the author's opinion on Supergenerics, an improved generic drugs which are often based on an incremental re-formulation of a generic active pharmaceutical ingredient (API). The author believes that supergenerics are significant in the future of the pharmaceutical industries...

  • Can Sterile Manufacturing Turn the Ship Around? Shanley, Agnes // Pharmaceutical Technology;Aug2015 Outsourcing Resources, ps48 

    An interview with James Agalloco, consultant at Agalloco and Associates Inc., is presented. He talks about lack of technical knowledge in pharmaceutical coampanies; perception of companies regarding the contract manufacturing organization (CMO) and challenge of old equipments used in the...

  • Biotech scientists bank on big pharma's biologics push. Wong, Grace // Nature Biotechnology;Mar2009, Vol. 27 Issue 3, p293 

    The article evaluates the ways in which large pharmaceutical companies and biotechnology scientists are turning to biologics as an area of growth. Numerous pharmaceutical companies have acquired biologics programs, including GlaxoSmithKline, AstraZeneca, and Pfizer. They are turning to this...

  • Finding Value in the Physician Relationship. Hicks, Cherie // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p26 

    In this article, the author reflects on the working professional working relationship between pharmaceutical representatives and physicians or other medical personnel. She stresses that the relationship, which created mutual benefits since physicians learned from the representatives the recent...

  • Reshaping the spending debate. Garnier, Jean-Pierre // Medical Marketing & Media;Oct2006, Vol. 41 Issue 10, p37 

    The author reflects on the debate over healthcare spending in which pharmaceutical companies are gaining recognition for its role in improving health by developing drugs. He argues that prevention lessens costs but it is important to continue to discover better treatments against disease. He...

  • Reinvigorating European R&D innovation. Kermani, Faiz // Pharmaceutical Technology Europe;Mar2010, Vol. 22 Issue 3, p10 

    The article looks at the declining phase and pace of research and development (R&D) programs in pharmaceutical industries in Europe. The author elaborates that government cost measures and risks of drug development have influenced companies to lie low in innovative research. On the other hand,...

  • Outside In. Newnham, David // Nursing Standard;10/4/2006, Vol. 21 Issue 4, p29 

    The article presents views and insights of the author concerning the inventiveness of pharmaceutical e-mail spam in Australia. The author relates his experiences when he received an e-mail promising him to supply all his pharmacy needs direct from the manufacturer. It also provides information...

  • Getting into bed with generics.  // European Chemical News;2/28/2005, Vol. 82 Issue 2136, p5 

    Addresses the need for the pharmaceutical industry to innovate to develop new and better medicines. Problems faced by the industry as of February 2005; Efforts of generics companies to capitalize on the growing numbers of products coming off patent; Factors believed to impede innovation within...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics